Kasinger James R.'s Form 4 filing
CRISPR Therapeutics AG (CRSP) · filed Feb 21, 2024
- Accession no.
- 0000950170-24-018175
- Filed
- Feb 21, 2024
- Trade date
- Feb 18-20, 2024
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $152.4K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kasinger James R.CIK 0001708172 | Officer (General Counsel and Secretary) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 18, 2024 | Common Shares | MOption exerciseAcquired | +3,825 | – | – | 59,284 | Direct | |
| Feb 20, 2024 | Common Shares | SSaleDisposed | −1,913 | $79.67 | −$152,408.71 | 57,371 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 18, 2024 | Common Shares | MOption exerciseDisposed | −3,825 | – | – | 7,650 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.